Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-1.A2 peptide vaccine
- Development stage
- Discontinued
- Lead developer
- Cliniques universitaires Saint-Luc
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
MAGE-1.A2 peptide vaccine is an investigational peptide-based therapeutic cancer vaccine developed by Cliniques Universitaires Saint-Luc (Université Catholique de Louvain) in Brussels, Belgium. The vaccine consists of a synthetic peptide corresponding to the HLA-A2-restricted epitope of the Melanoma-Associated Gene 1 (MAGE-1/MAGEA1) protein. It is designed to stimulate cytolytic T-lymphocyte (CTL) responses against melanoma cells expressing the MAGE-1 antigen. In clinical development, it was evaluated as part of an eight-peptide cocktail (including MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NA17.A2, Tyrosinase.A2, and NY-ESO-1.A2) administered with or without adjuvants such as Montanide ISA 51 and IMP321 (eftilagimod alpha) in a Phase 1/2 trial (NCT00365937) for disease-free, HLA-A2-positive cutaneous melanoma patients at high risk of relapse. The trial was terminated due to regulatory requirements from the peptide supplier.
- Other names
- MAGE-1.A2 peptideMAGE1.A2 peptideMAGE 1.A2 peptideMAGE-1.A2 antigenMAGE1.A2 antigenMAGE 1.A2 antigen
02
Targets
γδ TCR (T-cell receptor)HLA-A*01 (Human leukocyte antigen A*01:01)Melanoma-associated antigen 1 peptide-HLA class I complex
Beyond the preview
Go deeper on MAGE-1.A2 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-1.A2 peptide vaccine.